PMID- 25001880
OWN - NLM
STAT- MEDLINE
DCOM- 20150928
LR  - 20240213
IS  - 1473-1150 (Electronic)
IS  - 1470-269X (Print)
IS  - 1470-269X (Linking)
VI  - 15
IP  - 1
DP  - 2015 Feb
TI  - Clinical outcomes associated with proton pump inhibitor use among 
      clopidogrel-treated patients within CYP2C19 genotype groups following acute 
      myocardial infarction.
PG  - 20-5
LID - 10.1038/tpj.2014.28 [doi]
AB  - We examined clinical outcomes with proton pump inhibitors (PPI) use within 
      CYP2C19 genotype groups during clopidogrel treatment following acute myocardial 
      infarction (AMI). 2062 patients were genotyped for CYP2C19*2 and *17 variants in 
      TRIUMPH. 12 month clinical outcomes were analyzed among patients discharged on 
      clopidogrel within CYP2C19*2 carrier, CYP2C19*17 carrier, and CYP2C19*1 
      homozygote genotype groups. PPI use was not associated with a difference in 
      mortality. Among clopidogrel-treated Caucasians following AMI, PPI use was 
      associated with a significantly higher rate of cardiac rehospitalization (HR 
      1.62, 95% CI 1.19-2.19; P=0.002) compared with no PPI use. PPI users who were 
      carriers of the CYP2C19*17 variant experienced significantly higher rates of 
      cardiac rehospitalization (HR 2.05, 95% CI 1.26-3.33; P=0.003), carriers of the 
      CYP2C19*2 variant had a trend toward increased 1-year cardiac rehospitalization 
      (HR 1.69, 95% CI 0.95-2.99; P=0.07), while no significant differences were 
      observed among CYP2C19*1 homozygotes. These results indicate that the risks 
      associated with PPI use among clopidogrel-treated Caucasian post-MI patients are 
      impacted by CYP2C19 genotype, and suggest knowledge of genotype may be useful for 
      personalizing PPI use among patients following AMI to reduce rehospitalization.
FAU - Depta, J P
AU  - Depta JP
AD  - Washington University School of Medicine, Department of Medicine, St Louis, MO, 
      USA.
FAU - Lenzini, P A
AU  - Lenzini PA
AD  - Washington University School of Medicine, Department of Genetics, St Louis, MO, 
      USA.
FAU - Lanfear, D E
AU  - Lanfear DE
AD  - Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.
FAU - Wang, T Y
AU  - Wang TY
AD  - Duke Clinical Research Institute, Duke, Durham, NC, USA.
FAU - Spertus, J A
AU  - Spertus JA
AD  - Saint Luke's Mid America Heart Institute and the University of Missouri-Kansas 
      City, Kansas City, MO, USA.
FAU - Bach, R G
AU  - Bach RG
AD  - Washington University School of Medicine, Department of Medicine, St Louis, MO, 
      USA.
FAU - Cresci, S
AU  - Cresci S
AD  - 1] Washington University School of Medicine, Department of Medicine, St Louis, 
      MO, USA [2] Washington University School of Medicine, Department of Genetics, St 
      Louis, MO, USA.
LA  - eng
GR  - P50 HL077113/HL/NHLBI NIH HHS/United States
GR  - R01 HL103871/HL/NHLBI NIH HHS/United States
GR  - R01 NR013396/NR/NINR NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
DEP - 20140708
PL  - United States
TA  - Pharmacogenomics J
JT  - The pharmacogenomics journal
JID - 101083949
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - OM90ZUW7M1 (Ticlopidine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Clopidogrel
MH  - Cytochrome P-450 CYP2C19/*genetics
MH  - Female
MH  - *Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnosis/*drug therapy/*genetics
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
PMC - PMC4287459
MID - NIHMS598645
COIS- Conflicts of Interest: Jeremiah P. Depta: None Petra A. Lenzini: None David E. 
      Lanfear: None Tracy Y. Wang: Research Grants: Lilly USA (Significant), Daiichi 
      Sankyo (Significant), and Gilead Science (Significant); Consultant: Astra Zeneca 
      (Modest), American College of Cardiology Foundation (Significant) John A. 
      Spertus: Research Grants: Eli Lilly, EveHeart, Genentech, Gilead; Consultant: St. 
      Jude Medical (modest), United Healthcare (modest), Amgen (modest), Gilead 
      (modest), Genentech (modest), Janssen (modest), Novartis (modest); 
      Copyrights/Patents: Seattle Angina Questionnaire, Kansas City Cardiomyopathy 
      Questionnaire, Peripheral Artery Questionnaire, US Patents: 7,643,969; 7,853,456; 
      12/965,656; 13/615,401 Richard G. Bach: Research Grants: AstraZeneca, Eli Lilly, 
      Bristol-Myers Squibb, Merck/Schering-Plough; Consultant (CEC Activity only): 
      Roche (Significant), Pfizer (Modest) Sharon Cresci: None
EDAT- 2014/07/09 06:00
MHDA- 2015/09/29 06:00
PMCR- 2015/08/01
CRDT- 2014/07/09 06:00
PHST- 2014/01/06 00:00 [received]
PHST- 2014/04/09 00:00 [revised]
PHST- 2014/05/22 00:00 [accepted]
PHST- 2014/07/09 06:00 [entrez]
PHST- 2014/07/09 06:00 [pubmed]
PHST- 2015/09/29 06:00 [medline]
PHST- 2015/08/01 00:00 [pmc-release]
AID - tpj201428 [pii]
AID - 10.1038/tpj.2014.28 [doi]
PST - ppublish
SO  - Pharmacogenomics J. 2015 Feb;15(1):20-5. doi: 10.1038/tpj.2014.28. Epub 2014 Jul 
      8.